Characterization of E-cadherin expression in normal mucosa, dysplasia and adenocarcinoma of gastric cardia and its influence on prognosis

doi:10.4251/wjgo.v14.i1.265

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4095)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

198

WORD

HTML

1832

Figures (1-3)

209

Tables (1-4)

163

Sum=2480

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

287

Download

499

Sum=786

Publishing Process of This Article

Item

Count

Browse

290

Download

539

Sum=829

Jan 15, 2022 (publication date) through Apr 28, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jan 15, 2022; 14(1): 265-277
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.265

Characterization of E-cadherin expression in normal mucosa, dysplasia and adenocarcinoma of gastric cardia and its influence on prognosis

Hai-Ling Wang, Xue-Ke Zhao, Fu-You Zhou, Xin Song, Liu-Yu Li, Gai-Rong Huang, Qi-De Bao, Ling-Ling Lei, Hai-Jun Yang, Li Li, Rui-Hua Xu, Ai-Li Li, Xian-Zeng Wang, Wen-Li Han, Jing-Li Ren, Li-Dong Wang

Hai-Ling Wang, Xue-Ke Zhao, Xin Song, Liu-Yu Li, Ling-Ling Lei, Rui-Hua Xu, Wen-Li Han, Li-Dong Wang, State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China

Fu-You Zhou, Department of Thoracic Surgery and Tumor Prevention Treatment, Anyang Tumor Hospital, Anyang 455000, Henan Province, China

Gai-Rong Huang, Li Li, Department of Geriatrics, Henan Provincial People’s Hospital, Zhengzhou 450003, Henan Province, China

Qi-De Bao, Department of Oncology, Anyang District Hospital, Anyang 455000, Henan Province, China

Hai-Jun Yang, Department of Pathology, Anyang Tumor Hospital, Anyang 455000, Henan Province, China

Ai-Li Li, Department of Pathology, Linzhou Tumor Hospital, Linzhou 456500, Henan Province, China

Xian-Zeng Wang, Department of Thoracic Surgery, Linzhou People's Hospital, Linzhou 456500, Henan Province, China

Jing-Li Ren, Department of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China

Author contributions: Wang LD and Wang HL designed the study and wrote the paper; Zhao XK, Song X and Huang GR performed data collection; Bao QD, Lei LL and Yang HJ conducted follow-up of the patients; Li LY, Li L and Xu RH performed the tissue microarray; Zhou FY and Li AL performed the immunohistochemical analysis; Wang XZ, Han WL and Ren JL contributed to data analysis; Wang LD revised the manuscript.

Supported by National Natural Science Foundation of China, No. 81872032, and No. U1804262; and National Key R&D Program of China, No. 2016YFC0901403.

Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Zhengzhou University.

Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

Conflict-of-interest statement: We have no potential conflicts of interest to disclose.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Li-Dong Wang, MD, PhD, Professor, State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research, The First Affiliated Hospital of Zhengzhou University, No. 40 Daxue Road, Zhengzhou 450052, Henan Province, China. ldwang2007@126.com

Received: September 6, 2021
Peer-review started: September 6, 2021
First decision: November 8, 2021
Revised: November 18, 2021
Accepted: December 8, 2021
Article in press: December 8, 2021
Published online: January 15, 2022

Core Tip

Core Tip: In previous reports, there is no consistent conclusion on the association between E-cadherin expression and gastric cardia carcinogenesis and its effect on prognosis with gastric cardia adenocarcinoma (GCA) patients. It was notable that the positive immunostaining rates of E-cadherin decreased significantly from normal mucosa to dysplasia and GCA, as well as higher in early stage than those in advanced stage of GCA. Moreover, we found high expression of E–cadherin represented a better survival, especially for patients with negative lymph node metastasis. In conclusion, E-cadherin may be involved in carcinogenesis and may be a predictor on prognosis for GCA.